The receptor expression pattern in ductal carcinoma in situ predicts recurrence

Julie Kepple, Ronda S. Henry-Tillman, Vicki Klimberg, Rakshanda Layeeque, Eric Siegel, Kent Westbrook, Soheila Korourian

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: The treatment of ductal carcinoma in situ (DCIS) is based on size and pathologic morphology. We hypothesized that as with invasive breast cancer, receptor expression in DCIS is important for predicting recurrence. Methods: Retrospective review from 1990 through 2002 identified 94 DCIS patients who had documented estrogen receptor (ER), progesterone receptor (PR), p53, Her-2/neu (HER), tumor characteristics, type of surgery, use of radiation or tamoxifen, and site of recurrence. Results: Median age and tumor size was 57.5 years and 2.0 cm, respectively. Median follow-up was 4 years. Overall recurrence rate was 6%. The ER-positive/PR-negative/HER-positive receptor pattern represented 50% (3 of 6) of total recurrences (P = .01). The length of disease-free-survival in the ER-positive/PR-negative/HER-positive receptor pattern was significantly shorter than in the rest of the patients (P = .0011). Comments: Receptor expression may be important in DCIS for predicting recurrence. HER positivity, even with ER positivity, is significantly associated with a higher risk of recurrence.

Original languageEnglish (US)
Pages (from-to)68-71
Number of pages4
JournalAmerican Journal of Surgery
Volume192
Issue number1
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Recurrence
Estrogen Receptors
Progesterone Receptors
Tamoxifen
Disease-Free Survival
Neoplasms
Radiation
Breast Neoplasms

Keywords

  • Breast cancer
  • Ductal carcinoma in situ
  • Estrogen receptor
  • HER 2 neu receptor
  • Recurrence
  • Tamoxifen

ASJC Scopus subject areas

  • Surgery

Cite this

Kepple, J., Henry-Tillman, R. S., Klimberg, V., Layeeque, R., Siegel, E., Westbrook, K., & Korourian, S. (2006). The receptor expression pattern in ductal carcinoma in situ predicts recurrence. American Journal of Surgery, 192(1), 68-71. https://doi.org/10.1016/j.amjsurg.2006.04.002

The receptor expression pattern in ductal carcinoma in situ predicts recurrence. / Kepple, Julie; Henry-Tillman, Ronda S.; Klimberg, Vicki; Layeeque, Rakshanda; Siegel, Eric; Westbrook, Kent; Korourian, Soheila.

In: American Journal of Surgery, Vol. 192, No. 1, 07.2006, p. 68-71.

Research output: Contribution to journalArticle

Kepple, J, Henry-Tillman, RS, Klimberg, V, Layeeque, R, Siegel, E, Westbrook, K & Korourian, S 2006, 'The receptor expression pattern in ductal carcinoma in situ predicts recurrence', American Journal of Surgery, vol. 192, no. 1, pp. 68-71. https://doi.org/10.1016/j.amjsurg.2006.04.002
Kepple, Julie ; Henry-Tillman, Ronda S. ; Klimberg, Vicki ; Layeeque, Rakshanda ; Siegel, Eric ; Westbrook, Kent ; Korourian, Soheila. / The receptor expression pattern in ductal carcinoma in situ predicts recurrence. In: American Journal of Surgery. 2006 ; Vol. 192, No. 1. pp. 68-71.
@article{ccd4c5ddf8b542ccb917767ed4a4ba9c,
title = "The receptor expression pattern in ductal carcinoma in situ predicts recurrence",
abstract = "Background: The treatment of ductal carcinoma in situ (DCIS) is based on size and pathologic morphology. We hypothesized that as with invasive breast cancer, receptor expression in DCIS is important for predicting recurrence. Methods: Retrospective review from 1990 through 2002 identified 94 DCIS patients who had documented estrogen receptor (ER), progesterone receptor (PR), p53, Her-2/neu (HER), tumor characteristics, type of surgery, use of radiation or tamoxifen, and site of recurrence. Results: Median age and tumor size was 57.5 years and 2.0 cm, respectively. Median follow-up was 4 years. Overall recurrence rate was 6{\%}. The ER-positive/PR-negative/HER-positive receptor pattern represented 50{\%} (3 of 6) of total recurrences (P = .01). The length of disease-free-survival in the ER-positive/PR-negative/HER-positive receptor pattern was significantly shorter than in the rest of the patients (P = .0011). Comments: Receptor expression may be important in DCIS for predicting recurrence. HER positivity, even with ER positivity, is significantly associated with a higher risk of recurrence.",
keywords = "Breast cancer, Ductal carcinoma in situ, Estrogen receptor, HER 2 neu receptor, Recurrence, Tamoxifen",
author = "Julie Kepple and Henry-Tillman, {Ronda S.} and Vicki Klimberg and Rakshanda Layeeque and Eric Siegel and Kent Westbrook and Soheila Korourian",
year = "2006",
month = "7",
doi = "10.1016/j.amjsurg.2006.04.002",
language = "English (US)",
volume = "192",
pages = "68--71",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The receptor expression pattern in ductal carcinoma in situ predicts recurrence

AU - Kepple, Julie

AU - Henry-Tillman, Ronda S.

AU - Klimberg, Vicki

AU - Layeeque, Rakshanda

AU - Siegel, Eric

AU - Westbrook, Kent

AU - Korourian, Soheila

PY - 2006/7

Y1 - 2006/7

N2 - Background: The treatment of ductal carcinoma in situ (DCIS) is based on size and pathologic morphology. We hypothesized that as with invasive breast cancer, receptor expression in DCIS is important for predicting recurrence. Methods: Retrospective review from 1990 through 2002 identified 94 DCIS patients who had documented estrogen receptor (ER), progesterone receptor (PR), p53, Her-2/neu (HER), tumor characteristics, type of surgery, use of radiation or tamoxifen, and site of recurrence. Results: Median age and tumor size was 57.5 years and 2.0 cm, respectively. Median follow-up was 4 years. Overall recurrence rate was 6%. The ER-positive/PR-negative/HER-positive receptor pattern represented 50% (3 of 6) of total recurrences (P = .01). The length of disease-free-survival in the ER-positive/PR-negative/HER-positive receptor pattern was significantly shorter than in the rest of the patients (P = .0011). Comments: Receptor expression may be important in DCIS for predicting recurrence. HER positivity, even with ER positivity, is significantly associated with a higher risk of recurrence.

AB - Background: The treatment of ductal carcinoma in situ (DCIS) is based on size and pathologic morphology. We hypothesized that as with invasive breast cancer, receptor expression in DCIS is important for predicting recurrence. Methods: Retrospective review from 1990 through 2002 identified 94 DCIS patients who had documented estrogen receptor (ER), progesterone receptor (PR), p53, Her-2/neu (HER), tumor characteristics, type of surgery, use of radiation or tamoxifen, and site of recurrence. Results: Median age and tumor size was 57.5 years and 2.0 cm, respectively. Median follow-up was 4 years. Overall recurrence rate was 6%. The ER-positive/PR-negative/HER-positive receptor pattern represented 50% (3 of 6) of total recurrences (P = .01). The length of disease-free-survival in the ER-positive/PR-negative/HER-positive receptor pattern was significantly shorter than in the rest of the patients (P = .0011). Comments: Receptor expression may be important in DCIS for predicting recurrence. HER positivity, even with ER positivity, is significantly associated with a higher risk of recurrence.

KW - Breast cancer

KW - Ductal carcinoma in situ

KW - Estrogen receptor

KW - HER 2 neu receptor

KW - Recurrence

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=33745044215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745044215&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2006.04.002

DO - 10.1016/j.amjsurg.2006.04.002

M3 - Article

VL - 192

SP - 68

EP - 71

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 1

ER -